These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32486995)

  • 21. [Hydromorphone in Cancer Patients-A Retrospective Study].
    Sato N; Satomi E; Yoshida T; Shimizu M; Kiuchi D; Ishiki H
    Gan To Kagaku Ryoho; 2020 Dec; 47(12):1687-1690. PubMed ID: 33342984
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of the prescription opioid epidemic on young children: Trends and mortality.
    Wang GS; Olsen H; Severtson G; Green JL; Dart RC
    Drug Alcohol Depend; 2020 Jun; 211():107924. PubMed ID: 32178937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study.
    Gálvez R; Schäfer M; Hans G; Falke D; Steigerwald I
    Adv Ther; 2013 Mar; 30(3):229-59. PubMed ID: 23475406
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral oxycodone/naloxone for pain control in cirrhosis: Observational study in patients with symptomatic metastatic hepatocellular carcinoma.
    Tovoli F; De Lorenzo S; Samolsky Dekel BG; Piscaglia F; Benevento F; Brandi G; Bolondi L
    Liver Int; 2018 Feb; 38(2):278-284. PubMed ID: 28792650
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in consumption of opioid analgesics in Israel 2009 to 2016: An update focusing on oxycodone and fentanyl formulations.
    Ponizovsky AM; Marom E; Weizman A; Schwartzberg E
    Pharmacoepidemiol Drug Saf; 2018 May; 27(5):535-540. PubMed ID: 29488288
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pain management.
    Ripamonti CI
    Ann Oncol; 2012 Sep; 23 Suppl 10():x294-301. PubMed ID: 22987980
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Post-mortem analysis of prescription opioids-A follow-up examination by LC-MS/MS with focus on fentanyl.
    Schönfeld T; Heinemann A; Schulz M; Gradl G; Andresen-Streichert H; Müller A; Iwersen-Bergmann S
    Forensic Sci Int; 2019 Dec; 305():109970. PubMed ID: 31629200
    [TBL] [Abstract][Full Text] [Related]  

  • 28. What Parenteral Opioids to Use in Face of Shortages of Morphine, Hydromorphone, and Fentanyl.
    Davis MP; McPherson ML; Mehta Z; Behm B; Fernandez C
    Am J Hosp Palliat Care; 2018 Aug; 35(8):1118-1122. PubMed ID: 29649890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trends in medical use and abuse of opioid analgesics.
    Joranson DE; Ryan KM; Gilson AM; Dahl JL
    JAMA; 2000 Apr; 283(13):1710-4. PubMed ID: 10755497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evidence of morphine metabolism to hydromorphone in pain patients chronically treated with morphine.
    Cone EJ; Heit HA; Caplan YH; Gourlay D
    J Anal Toxicol; 2006; 30(1):1-5. PubMed ID: 16620524
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Opioid-induced inhibition of the human 5-HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome.
    Rickli A; Liakoni E; Hoener MC; Liechti ME
    Br J Pharmacol; 2018 Feb; 175(3):532-543. PubMed ID: 29210063
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites.
    Smith MT
    Clin Exp Pharmacol Physiol; 2000 Jul; 27(7):524-8. PubMed ID: 10874511
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combatting pain after orthopedic/trauma surgery- perioperative oral extended-release tapentadol vs. extended-release oxycodone/naloxone.
    Haeseler G; Schaefers D; Prison N; Ahrens J; Liu X; Karch A
    BMC Anesthesiol; 2017 Jul; 17(1):91. PubMed ID: 28693439
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Conversion Ratio From Intravenous Hydromorphone to Oral Opioids in Cancer Patients.
    Reddy A; Vidal M; Stephen S; Baumgartner K; Dost S; Nguyen A; Heung Y; Kwan S; Wong A; Pangemanan I; Azhar A; Tayjasanant S; Rodriguez E; Waletich J; Lim KH; Wu J; Liu D; Williams J; Yennurajalingam S; Bruera E
    J Pain Symptom Manage; 2017 Sep; 54(3):280-288. PubMed ID: 28711751
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of oxycodone and oxycodone/naloxone in cancer pain management.
    Leppert W
    Pharmacol Rep; 2010; 62(4):578-91. PubMed ID: 20884999
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methadone, Buprenorphine, Oxycodone, Fentanyl and Tramadol in Multiple Postmortem Matrices.
    Havig SM; Vindenes V; Øiestad ÅML; Rogde S; Thaulow CH
    J Anal Toxicol; 2022 Jul; 46(6):600-610. PubMed ID: 34115841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does tapentadol affect sex hormone concentrations differently from morphine and oxycodone? An initial assessment and possible implications for opioid-induced androgen deficiency.
    Eichenbaum G; Göhler K; Etropolski M; Steigerwald I; Pergolizzi J; Kim M; Vorsanger G
    J Opioid Manag; 2015; 11(3):211-27. PubMed ID: 25985806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rational use of sublingual opioids in palliative medicine.
    Reisfield GM; Wilson GR
    J Palliat Med; 2007 Apr; 10(2):465-75. PubMed ID: 17472518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adverse effects in hospice patients with chronic kidney disease receiving hydromorphone.
    Paramanandam G; Prommer E; Schwenke DC
    J Palliat Med; 2011 Sep; 14(9):1029-33. PubMed ID: 21823925
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolism and Disposition of Prescription Opioids: A Review.
    DePriest AZ; Puet BL; Holt AC; Roberts A; Cone EJ
    Forensic Sci Rev; 2015 Jul; 27(2):115-45. PubMed ID: 26227254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.